{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Care+Regimen+9+Months", "query": { "intervention": "Standard Care Regimen 9 Months" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 22, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Care+Regimen+9+Months&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T13:42:35.108Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06592599", "title": "Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "Toripalimab", "type": "DRUG" }, { "name": "Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-09-03", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-04T13:42:35.108Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06592599" }, { "nct_id": "NCT00130273", "title": "Managed Problem Solving to Increase Treatment Adherence in Individuals With HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Managed problem solving", "type": "BEHAVIORAL" }, { "name": "Standard care", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2005-07", "completion_date": "2011-02", "has_results": false, "last_update_posted_date": "2012-07-13", "last_synced_at": "2026-10-04T13:42:35.108Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00130273" }, { "nct_id": "NCT06859424", "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AML (Acute Myelogenous Leukemia)", "Acute Lymphoid Leukemia (ALL)", "Acute Leukemia (Category)", "MDS (Myelodysplastic Syndrome)", "CML (Chronic Myelogenous Leukemia)", "CLL (Chronic Lymphocytic Leukemia)", "Prolymphocyctic Leukemia", "Chronic Myelomonocytic Leukemia (CMML)", "Myeloproliferative Neoplasm (MPN)", "Lymphoma", "Myelofibrosis" ], "interventions": [ { "name": "Conditioning Regimen A", "type": "DRUG" }, { "name": "Conditioning Regimen B", "type": "DRUG" }, { "name": "Conditioning Regimen C", "type": "DRUG" }, { "name": "Conditioning Regimen D", "type": "DRUG" }, { "name": "Conditioning Regimen E", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "PTCy (50 mg/kg D3, D4)", "type": "DRUG" }, { "name": "PTCy (25 mg/kg D3, D4)", "type": "DRUG" }, { "name": "Post-transplant Tacrolimus", "type": "DRUG" }, { "name": "Post-transplant Mycophenolate mofetil", "type": "DRUG" }, { "name": "Post-transplant Abatacept", "type": "DRUG" }, { "name": "Post-transplant Ruxolitinib", "type": "DRUG" }, { "name": "Supportive Care: Growth Factors", "type": "DRUG" }, { "name": "Supportive Care: Blood Products", "type": "PROCEDURE" }, { "name": "Supportive Care: Infection Prophylaxis", "type": "OTHER" }, { "name": "Supportive Care: Intravenous immune globulin (IVIG)", "type": "OTHER" }, { "name": "Supportive Care: Seizure prophylaxis", "type": "DRUG" }, { "name": "Supportive Care: Monitoring and management of CRS", "type": "OTHER" }, { "name": "Supportive Care: Prophylaxis against infections", "type": "OTHER" }, { "name": "Supportive Care: Prophylaxis against infections", "type": "DRUG" }, { "name": "Supportive Care: Lipid elevations", "type": "OTHER" }, { "name": "Study treatment compliance", "type": "OTHER" }, { "name": "Prohibited Concomitant Therapy", "type": "OTHER" }, { "name": "Permitted Concomitant Therapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 358, "start_date": "2025-07-25", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-04T13:42:35.108Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06859424" }, { "nct_id": "NCT01335685", "title": "Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2011-06-27", "completion_date": "2016-12-29", "has_results": true, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-10-04T13:42:35.108Z", "location_count": 2, "location_summary": "Lebanon, New Hampshire • Morgantown, West Virginia", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01335685" }, { "nct_id": "NCT02410772", "title": "TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tuberculosis" ], "interventions": [ { "name": "rifapentine", "type": "DRUG" }, { "name": "rifapentine and moxifloxacin", "type": "DRUG" }, { "name": "control", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centers for Disease Control and Prevention", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 2516, "start_date": "2016-01-25", "completion_date": "2021-05", "has_results": true, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-10-04T13:42:35.108Z", "location_count": 5, "location_summary": "San Francisco, California • New York, New York • Fort Worth, Texas + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Fort Worth", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02410772" }, { "nct_id": "NCT01509599", "title": "Cooling Lower Leg Skin to Prevent Venous Leg Ulcers in Patients With Poor Vein Circulation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Venous Disease", "Venous Vascular Diseases and Syndromes", "Venous Insufficiency", "Venous Ulcers" ], "interventions": [ { "name": "Cryotherapy: Cooling gel wrap", "type": "PROCEDURE" }, { "name": "Usual care", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 197, "start_date": "2011-08", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-04-05", "last_synced_at": "2026-10-04T13:42:35.108Z", "location_count": 2, "location_summary": "Charleston, South Carolina • Spartanburg, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01509599" }, { "nct_id": "NCT03446638", "title": "iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "FDA-approved drug or combination of drugs", "type": "DRUG" }, { "name": "FLAG induction", "type": "DRUG" }, { "name": "7 + 3 induction", "type": "DRUG" }, { "name": "Low-dose cytarabine", "type": "DRUG" }, { "name": "Supportive care alone", "type": "OTHER" }, { "name": "Computational biology simulations software", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "OTHER", "DEVICE" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2019-05", "completion_date": "2022-09", "has_results": false, "last_update_posted_date": "2019-06-11", "last_synced_at": "2026-10-04T13:42:35.108Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03446638" }, { "nct_id": "NCT02646488", "title": "Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiovascular Disease", "High Blood Pressure" ], "interventions": [ { "name": "Million Hearts ABCS 6 Months", "type": "BEHAVIORAL" }, { "name": "Million Hearts ABCS 9 Months", "type": "BEHAVIORAL" }, { "name": "Million Hearts ABCS 12 Months", "type": "BEHAVIORAL" }, { "name": "Million Hearts ABCS 15 Months", "type": "BEHAVIORAL" }, { "name": "Standard Care Regimen 9 Months", "type": "BEHAVIORAL" }, { "name": "Standard Care Regimen 12 Months", "type": "BEHAVIORAL" }, { "name": "Standard Care Regimen 15 Months", "type": "BEHAVIORAL" }, { "name": "Standard Care Regimen 18 Months", "type": "BEHAVIORAL" }, { "name": "Standard Care Regimen 21 Months", "type": "BEHAVIORAL" }, { "name": "Standard Care Regimen 24 Months", "type": "BEHAVIORAL" }, { "name": "Standard Care Regimen 27 Months", "type": "BEHAVIORAL" }, { "name": "Follow Up Post Intervention 21 Months", "type": "BEHAVIORAL" }, { "name": "Follow Up Post Intervention 24 Months", "type": "BEHAVIORAL" }, { "name": "Follow Up Post Intervention 27 Months", "type": "BEHAVIORAL" }, { "name": "Follow Up Post Intervention 30 Months", "type": "BEHAVIORAL" }, { "name": "Follow Up Post Intervention 33 Months", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 276, "start_date": "2015-08", "completion_date": "2019-04-01", "has_results": false, "last_update_posted_date": "2019-05-20", "last_synced_at": "2026-10-04T13:42:35.108Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02646488" }, { "nct_id": "NCT04833907", "title": "rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Canavan Disease" ], "interventions": [ { "name": "rAAV-Olig001-ASPA", "type": "DRUG" }, { "name": "Levetiracetam", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myrtelle Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "60 Months", "sex": "ALL", "summary": "3 Months to 60 Months" }, "enrollment_count": 24, "start_date": "2021-04-01", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-10-04T13:42:35.108Z", "location_count": 1, "location_summary": "Dayton, Ohio", "locations": [ { "city": "Dayton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04833907" }, { "nct_id": "NCT02013167", "title": "Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Standard of Care Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 405, "start_date": "2014-01-03", "completion_date": "2017-03-14", "has_results": true, "last_update_posted_date": "2024-03-05", "last_synced_at": "2026-10-04T13:42:35.108Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02013167" } ] }